AlphaCentric Advisors’s Bristol-Myers Squibb BMY Stock Holding History

AlphaCentric Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.11M	Buy	+19,649	New	+$1.1M	1.11%	24
2023 Q4	–	Sell	-3,153	Closed	-$183K	–	234
2023 Q3	$183K	Sell	3,153 -95	-3%	-$5.82K	0.1%	156
2023 Q2	$208K	Sell	3,248 -231	-7%	-$15.5K	0.12%	146
2023 Q1	$241K	Sell	3,479 -39	-1%	-$2.75K	0.17%	132
2022 Q4	$253K	Buy	+3,518	New	+$265K	0.25%	121
2021 Q4	$748K	Buy	12,000 +11,290	+1,590%	+$662K	0.22%	47
2021 Q3	$42K	Hold	710	–	–	0.01%	192
2021 Q2	$47K	Hold	710	–	–	0.01%	202
2021 Q1	$45K	Hold	710	–	–	0.02%	196
2020 Q4	$44K	Hold	710	–	–	0.02%	187
2020 Q3	$43K	Hold	710	–	–	0.02%	117
2020 Q2	$42K	Buy	+710	New	+$42.5K	0.02%	93

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCentric Advisors's BMY Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Bristol-Myers Squibb (BMY) in Q4 2024: 19,649 shares worth $1.11M. The stake represents 1.11% of the portfolio and ranks #24 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in BMY as recently as Q3 2023.

AlphaCentric Advisors first reported a position in BMY in Q2 2020 and has held it in 12 quarters since. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

AlphaCentric Advisors held 19,649 shares of Bristol-Myers Squibb worth $1.11M as of Q4 2024.
Bristol-Myers Squibb was a new AlphaCentric Advisors position in Q4 2024.
Bristol-Myers Squibb made up 1.11% of AlphaCentric Advisors's portfolio in Q4 2024, its #24 holding.
AlphaCentric Advisors first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 12 quarters since.
2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.